Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable (Stage III) Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06199713
What this trial is testing

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Who this might be right for
MelanomaMelanoma Stage IIIMelanoma Stage IV+1 more
University of Wisconsin, Madison 24
Early research (Phase 1)Study completedNCT01489059
What this trial is testing

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 42
Early research (Phase 1)Active Not RecruitingNCT02721459
What this trial is testing

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Who this might be right for
MelanomaSkin Cancer
H. Lee Moffitt Cancer Center and Research Institute 26
Testing effectiveness (Phase 2)Ended earlyNCT00505635
What this trial is testing

Biochemotherapy With Temozolomide for Metastatic Melanoma

Who this might be right for
Melanoma
M.D. Anderson Cancer Center 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT03767348
What this trial is testing

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)+1 more
Replimune, Inc. 340
Large-scale testing (Phase 3)Study completedNCT00111007
What this trial is testing

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
Bayer 270
Early research (Phase 1)WithdrawnNCT01843738
What this trial is testing

Radiation Use During Vemurafenib Treatment

Who this might be right for
BRAFV600 MutationStage IV Melanoma
University of Utah
Testing effectiveness (Phase 2)Study completedNCT00135408
What this trial is testing

MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Who this might be right for
Malignant Melanoma
Bristol-Myers Squibb 115
Testing effectiveness (Phase 2)Ended earlyNCT06984328
What this trial is testing

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Who this might be right for
Cutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)
Genmab 1
Testing effectiveness (Phase 2)Ended earlyNCT02587650
What this trial is testing

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Who this might be right for
ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more
University of California, San Francisco 1
Testing effectiveness (Phase 2)Study completedNCT00261365
What this trial is testing

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Who this might be right for
Unresectable Stage III or IV Malignant Melanoma
Bristol-Myers Squibb 80
Testing effectiveness (Phase 2)UnknownNCT00086866
What this trial is testing

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Who this might be right for
Melanoma (Skin)
European Organisation for Research and Treatment of Cancer - EORTC 165
Testing effectiveness (Phase 2)Ended earlyNCT02414750
What this trial is testing

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Netherlands Working Group on Immunotherapy of Oncology 78
Testing effectiveness (Phase 2)UnknownNCT03190824
What this trial is testing

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Who this might be right for
Melanoma Stage IIIMelanoma Stage Iv
Syneos Health 4
Testing effectiveness (Phase 2)Study completedNCT01950390
What this trial is testing

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Who this might be right for
Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Melanoma
National Cancer Institute (NCI) 169
Testing effectiveness (Phase 2)Ended earlyNCT03325101
What this trial is testing

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Who this might be right for
Stage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7+2 more
Mayo Clinic 7
Testing effectiveness (Phase 2)Ended earlyNCT01316692
What this trial is testing

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Who this might be right for
Recurrent MelanomaStage IIIc MelanomaStage IV Melanoma
Vanderbilt-Ingram Cancer Center 12
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Large-scale testing (Phase 3)Study completedNCT01909453
What this trial is testing

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Who this might be right for
Melanoma
Pfizer 921
Testing effectiveness (Phase 2)Study completedNCT02902029
What this trial is testing

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Who this might be right for
Malignant Melanoma
University Hospital, Essen 186
Next Page